Related Experiment Video
Updated: Aug 10, 2026

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
Published on: January 15, 2010
Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice
Abstract:
The histochemical, biochemical and behavioural consequences of MPTP administration in C-57 black mice was assessed 0.5 h, 24 h and 7 days after the last injection of this drug administered daily for 10 days during a 12 day period (30 mg/kg/injection or vehicle). A slight but significant impairment of open field performance was observed at 0.5 h after the last injection of MPTP while a facilitation of locomotory behaviour was observed only in the 24 h post-injection group. Striatal dopamine levels were reduced to 14, 18 and 27% of control levels in the 0.5 h, 24 h and 7 day post-MPTP treated groups, respectively. Histochemical assessment was in agreement with the biochemical assay results in that all MPTP treated animals showed severe depletion of striatal terminal fields. Other terminal fields were occasionally affected by MPTP treatment and only rarely was any change in the fluorescence or morphology of nigral cell bodies seen. Accumulation of amines in the degenerating amine-containing axons which traverse the lateral hypothalamus was not seen in any of the MPTP treated animals. These results indicate that, in the C-57 black mouse, MPTP causes a depletion of striatal dopamine without causing nigral cell loss or axon swelling as is observed with other experimental treatments such as 6-hydroxydopamine. Consistent with this is the behavioural data, indicating that severe deficits in motor function which are associated with nigrostriatal cell loss were not seen.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
MPTP administration in mice depleted striatal dopamine levels and affected locomotion. Unlike other neurotoxins, MPTP did not cause nigral cell loss or axon swelling in this study.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin used to model Parkinson's disease.
- Understanding MPTP's effects is crucial for Parkinson's disease research.
Purpose of the Study:
- To investigate the histochemical, biochemical, and behavioral effects of MPTP in C-57 black mice.
- To compare MPTP's neurotoxic profile with other agents like 6-hydroxydopamine.
Main Methods:
- Daily MPTP administration (30 mg/kg) or vehicle for 10 days.
- Behavioral assessment (open field test) at 0.5h, 24h, and 7 days post-injection.
- Biochemical assays for striatal dopamine levels.
- Histochemical analysis of brain tissue.
Main Results:
- MPTP significantly reduced striatal dopamine levels (14-27% of control).
- Behavioral changes included initial locomotion impairment and later facilitation.
- Histochemistry confirmed severe depletion of striatal dopamine terminals without nigral cell body damage or axon swelling.
Conclusions:
- MPTP induces striatal dopamine depletion and behavioral alterations in C-57 black mice.
- MPTP's mechanism differs from 6-hydroxydopamine, as it spares nigral neurons and axons.
- The observed effects suggest MPTP causes dopamine terminal damage without significant neuronal loss in this model.

